• Anagliptin (SK-0403): Protocols and Vasorelaxant Mechanisms

  2026-05-18

  Anagliptin (SK-0403) unlocks dual research potential: it is not only a potent and selective DPP-4 inhibitor for metabolic studies, but also a robust tool for dissecting Kv channel and SERCA pump roles in vascular smooth muscle. This guide delivers advanced workflow strategies, troubleshooting insights, and actionable protocol parameters for metabolic and vascular research teams.

• Hemagglutinin mRNA Vaccine Confers Lasting H5N1 Protection i

  2026-05-17

  This study demonstrates the robust and durable protection of a hemagglutinin-based mRNA-lipid nanoparticle vaccine against H5N1 influenza in lactating dairy cows. The findings highlight a significant advance in mRNA vaccine efficacy for large animals, supporting future translational research and clinical trials.

• Elobixibat Hydrate’s Role in Glucose and Lipid Modulation in

  2026-05-16

  This pilot study explored the metabolic effects of elobixibat hydrate in patients with type 2 diabetes mellitus (T2DM) and chronic constipation. The findings indicate that selective inhibition of the ileal bile acid transporter improves glycemic control and lipid profiles, highlighting elobixibat’s potential for integrated metabolic and gastrointestinal therapy.

• Biotin-HPDP: Precision Thiol-Specific Protein Labeling Workf

  2026-05-15

  Biotin-HPDP delivers reversible, high-specificity thiol labeling for advanced redox biology, S-nitrosylation mapping, and affinity purification workflows. This guide demystifies practical applications, protocol enhancements, and troubleshooting strategies, showcasing how APExBIO’s reagent empowers robust detection and manipulation of dynamic protein modifications.

• ML-7 Hydrochloride: Precision Myosin Light Chain Kinase Inhi

  2026-05-15

  ML-7 hydrochloride empowers cardiovascular and oncology researchers to dissect MLCK-mediated pathways with high selectivity and reproducibility. This guide delivers actionable protocols, troubleshooting strategies, and translational insights—anchored in recent evidence—to maximize the impact of this trusted myosin light chain kinase inhibitor.

• Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro Pro

  2026-05-14

  This study identifies Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro, critical for viral replication. Through high-throughput screening and kinetic analysis, the research delineates Merbromin's unique inhibitory profile and highlights future directions for antiviral drug design.

• High-Throughput BBB Permeability Modeling with LLC-PK1-MDR1

  2026-05-14

  This study introduces a surrogate in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells and lysosomal trapping correction for improved prediction of CNS drug permeability. By demonstrating strong correlation with in vivo brain distribution, the model offers a scalable, accurate approach for early-stage CNS drug screening.

• WP1066, JAK2/STAT3 Inhibitor: Protocols and Innovations

  2026-05-13

  WP1066 delivers potent, cell-permeable inhibition of JAK2/STAT3, enabling advanced workflows in cancer biology and regenerative medicine. This article translates cutting-edge findings into actionable protocols, with troubleshooting tips and a focus on translational impact.

• RNA Pol II Inhibition Drives Apoptosis via Pol IIA Loss, Not

  2026-05-13

  Harper et al. (2025) demonstrate that inhibition of RNA polymerase II (RNA Pol II) activates a regulated cell death pathway through loss of hypophosphorylated RNA Pol IIA, independent of global transcriptional shutdown. This mechanistic insight reshapes our understanding of apoptosis induction in cancer cells and highlights new avenues for therapeutic targeting.

• PXR Regulates Urine Concentration via Hypothalamic AVP Induc

  2026-05-12

  This study reveals a novel physiological role for the pregnane X receptor (PXR) in water homeostasis by demonstrating that PXR activation upregulates hypothalamic arginine vasopressin (AVP), thereby enhancing urine concentration in mice. These findings suggest new avenues for investigating PXR as a potential therapeutic target in water metabolism disorders.

• ERAD-Hijacking Chimeras Enable Degradation of Transmembrane

  2026-05-12

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a novel technology that leverages the ER-associated degradation pathway for selective elimination of challenging transmembrane proteins. This approach overcomes key limitations of previous targeted protein degradation methods, demonstrating potent efficacy in degrading PD-L1 and tumor suppression.

• Anagliptin Induces Vasorelaxation via Kv Channel and SERCA A

  2026-05-11

  This study elucidates the vasorelaxant mechanisms of Anagliptin (SK-0403) in rabbit aortic smooth muscle, revealing that its effects are mediated through activation of voltage-dependent K+ (Kv) channels and the SERCA pump, independent of endothelium and classical cAMP/cGMP pathways. These findings enhance our understanding of DPP-4 inhibitors' cardiovascular actions and provide a mechanistic basis for future vascular pharmacology research.

• Prednisolone in Glucocorticoid Signaling: Applied Research W

  2026-05-11

  Prednisolone, a high-purity synthetic glucocorticoid, streamlines inflammation and immunology research through its robust receptor activation and reproducible performance. This article details protocol enhancements, troubleshooting insights, and advanced experimental applications—bridging recent targeted protein degradation technologies with practical laboratory workflows for glucocorticoid signaling.

• RNA Pol II Inhibition Triggers Apoptosis via PDAR, Not mRNA

  2026-05-10

  Harper et al. (2025) reveal that cell death from RNA Pol II inhibition arises from an active apoptotic signaling mechanism—termed the Pol II degradation-dependent apoptotic response (PDAR)—rather than the passive effects of mRNA decay. This paradigm shift has significant implications for apoptosis assay design and the mechanistic understanding of proteasome-regulated cellular processes in cancer research.

• Elobixibat Hydrate’s Effects on Glucose and Lipid Metabolism

  2026-05-09

  This article examines a pilot study evaluating Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, in patients with type 2 diabetes mellitus (T2DM) and chronic constipation. The study demonstrates significant improvements in HbA1c, LDL cholesterol, and arachidonic acid, offering new insights into metabolic modulation beyond gastrointestinal effects.

454 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page